Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNSC-IL7
- Development stage
- Preclinical
- Lead developer
- Kennedy Krieger Institute
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
iNSC-IL7 is an experimental cellular immunotherapy consisting of human induced pluripotent stem cell (iPSC)-derived neural stem cells (iNSCs) engineered to deliver the immunostimulatory cytokine interleukin-7 (IL7). Developed for the treatment of glioblastoma (GBM), the therapy leverages the innate tumor-homing capabilities of neural stem cells to provide localized, intratumoral delivery of IL7. This approach aims to overcome the immunologically "cold" tumor microenvironment characteristic of GBM by increasing cytotoxic CD8+ T cell infiltration and activity. Preclinical studies in syngeneic mouse models have demonstrated significant tumor regression and extended survival, particularly when combined with immune checkpoint inhibitors like anti-PD-1 or anti-CTLA-4 antibodies.
- Other names
- human iPS cell-derived neural stem cells delivering interleukin-7
02
Targets
IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on iNSC-IL7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNSC-IL7.